HR 2443
114th Congress • 2015-2017 (Ended)

To amend the Federal Food, Drug, and Cosmetic Act with respect to CLIA waiver study design guidance for in vitro diagnostics.


HR 2443
May 19, 2015
Referred to the Subcommittee on Health.